NAB1

Across TCGA pan-cancer cohorts, NAB1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NAB1 data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher NAB1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NAB1 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

STAD, COAD, and LGG are the cancer types where NAB1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.003	0.667	<.001	18	view →
COAD	OS	Median	All	0.168	0.799	.004	12	view →
LGG	OS	Median	All	0.294	0.811	.004	6	view →
LIHC	DFS	Median	All	0.182	0.556	.022	6	view →
BLCA	DFS	Median	All	1.000	0.327	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NAB1–STAD (OS)

Open the STAD breakdown →